Ramucirumab for Carcinomas: A Journey to Unfold

Dear Dr. Renukaprasad A R, Are you aware of the recommended indications for ramucirumab? 2nd line advanced gastric cancer (GC)/gastroesophageal junction adenocarcinoma 1st line epidermal growth factor receptor mutation-positive (EGFRm+) metastatic non-small-cell lung cancer (NSCLC) 2nd line locally advanced or metastatic NSCLC 2nd line metastatic colorectal cancer 2nd line advanced or unresectable hepatocellular carcinoma Join the experts for a detailed discussion on managing EGFRm+ advanced NSCLC and GC with Ramucirumab, TODAY at 07:30 PM IST. We look forward to your active participation Highlights: Outline of ramucirumab's Journey in India Case study: Ramucirumab as second-line GC treatment Improve treatment options for EGFRm+ advanced NSCLC - RELAYing RELAY Join the Session   India's Largest Online Community of Verified Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*